The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Multiplexed immunohistochemistry (mIHC) analysis and clinical outcomes of nelmastobart in combination with trifluridine/tipiracil and bevacizumab in patients with refractory colorectal cancer (phase 1b/2).
 
Soohyeon Lee
Stock and Other Ownership Interests - Celgene/Bristol-Myers Squibb; Pfizer
Consulting or Advisory Role - DreamCIS; Takeda
Research Funding - Amgen; ST Cube; Yuhan Co
Travel, Accommodations, Expenses - ST Cube
 
Keun-Wook Lee
Honoraria - Astellas Pharma; Bayer; Celltrion; Merck KGaA; MSD Oncology; Ono Pharmaceutical
Consulting or Advisory Role - Abbvie; Astellas Pharma; BeiGene; Daiichi Sankyo; Metafines; MSD; Ono Pharmaceutical; PIN therapeutics; Takeda
Research Funding - ALX Oncology (Inst); Amgen (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Avelos Therapeutics (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Erasca, Inc (Inst); Exelixis (Inst); Genome & Company (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); IDRx (Inst); IgM Biosciences (Inst); Ildong Pharmaceutical (Inst); InventisBio (Inst); Jazz Pharmaceuticals (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Leap Therapeutics (Inst); Medicenna (Inst); MedPacto (Inst); Merck KGaA (Inst); Metafines (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Panolos Bioscience (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst); Torl Biotherapeutics (Inst); Trishula Therapeutics (Inst); Wellmarker Bio (Inst); Yuhan (Inst)
(OPTIONAL) Uncompensated Relationships - ALX Oncology
 
Sae-Won Han
Stock and Other Ownership Interests - IMBdx
Consulting or Advisory Role - Abbvie; AstraZeneca; IMBdx; Natera
Research Funding - Abbvie (Inst); Arcus Biosciences (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); BeyondBio (Inst); Boryung (Inst); Cell Biotech (Inst); GC Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hanmi (Inst); Hengrui Pharmaceutical (Inst); IMBdx (Inst); Janssen (Inst); Jeil Pharmaceutical Co (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck KGaA (Inst); Mirati Therapeutics (Inst); MSD (Inst); Roche (Inst); Seagen (Inst)
 
Seung-Hoon Beom
Honoraria - Astellas Pharma; Jeil Pharmaceutical Co; Takeda
Consulting or Advisory Role - Amgen; Astellas Pharma; Guardant Health; IMBdx; Jeil Pharmaceutical Co; Ono Pharmaceutical
Research Funding - Amgen (Inst); Bayer (Inst); IgM Biosciences (Inst); Jeil Pharmaceutical Co (Inst); Johnson & Johnson/Janssen (Inst); Merck (Inst); MSD (Inst); Pfizer (Inst); Revolution Medicines (Inst); Roche (Inst); ST Cube (Inst); Takeda (Inst)
 
Sun Young Kim
Consulting or Advisory Role - AstraZeneca; Merck; Natera; Roche
Research Funding - Roche/Genentech (Inst)
Expert Testimony - Guardant Health
 
Stephen Yoo
Employment - Jiyoung H. Yoo (I); Stephen S. Yoo
Leadership - Jiyoung H. Yoo (I); Stephen S. Yoo
Stock and Other Ownership Interests - Jiyoung H. Yoo; Stephen S. Yoo
Patents, Royalties, Other Intellectual Property - Stephen S. Yoo